25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in mice.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The possible involvement of the PI3K/AKT/BDNF/VGF signaling in rapid-acting antidepressant-like effects of antidepressants has been explored progressively by more studies. However, whether this signaling participates in the antidepressant-like effects of acetyl-l-carnitine (ALC) has not been examined. Herein, we assessed the antidepressant-like effects of ALC using the forced swimming test (FST). Our results demonstrated the dose-effect relationship of acute administration of ALC (5, 25, 50 and 100mg/kg, i.p.) and showed that it dose-dependently decreased the immobility time on FST of mice. In addition, ALC (100 mg/kg, i.p.) also reversed depressive-like behavior and the down-regulation of phosphorylated AKT (pAKT), brain-derived neurotrophic factor (BDNF) and neuropeptide VGF in the hippocampus and prefrontal cortex of mice induced by chronic unpredictable mild stress (CUMS) paradigm. Further, intra-cerebroventricular (i.c.v.) infusions of LY294002 (10 nmol/side), a specific phosphatidylinositol 3-kinase (PI3K) inhibitor, significantly prevented the antidepressant-like effect of ALC (100mg/kg, i.p.). In conclusion, our results demonstrated that ALC exerts rapid-acting antidepressant-like effects that might be mediated by the PI3K/AKT/BDNF/VGF signaling pathway.

          Related collections

          Author and article information

          Journal
          Neuroscience
          Neuroscience
          1873-7544
          0306-4522
          Jan 29 2015
          : 285
          Affiliations
          [1 ] Department of Pharmacy, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, PR China; Department of Pharmacy, Henan Cancer Hospital, Zhengzhou 450008, PR China; Ningbo Key Lab of Behavioral Neuroscience, Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China; Zhejiang Provincial Key Laboratory of Pathophysiology in Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China.
          [2 ] Ningbo Key Lab of Behavioral Neuroscience, Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China; Zhejiang Provincial Key Laboratory of Pathophysiology in Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China.
          [3 ] Ningbo Key Lab of Behavioral Neuroscience, Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China; Zhejiang Provincial Key Laboratory of Pathophysiology in Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China. Electronic address: wanglovechuang@163.com.
          [4 ] Ningbo Key Lab of Behavioral Neuroscience, Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China; Zhejiang Provincial Key Laboratory of Pathophysiology in Ningbo University School of Medicine, 818 Fenghua Road, Ningbo, Zhejiang 315211, PR China. Electronic address: wangqinwen@nbu.edu.cn.
          Article
          S0306-4522(14)00991-9
          10.1016/j.neuroscience.2014.11.025
          25463525
          f3b17a57-dda0-4ada-a327-1f0ea53ce6e0
          Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.
          History

          acetyl-l-carnitine,brain-derived neurotrophic factor,depression,neuropeptide VGF,phosphatidylinositol 3-kinase

          Comments

          Comment on this article